Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Raluca Ioana Draghici
International
www.shutterstock.com
Always see our news on Google
The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
20:49
Russia requests clarifications from Washington and Ankara regarding possible plans to transfer an arsenal of American weapons to Kiev
20:29
Donald Tusk declared that the Polish army will become the largest in Europe
20:14
The price of diesel decreases by 68 bani per liter, announces Bogdan Ivan
19:58
Abu Dhabi accuses Iran of piracy after three tankers of the Adnoc company from the United Arab Emirates were attacked in the Strait of Hormuz
19:42
Italian Eurofighters complete their mission in Romania after 300 flight hours / Spain takes over the air defense of the eastern flank
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
